FDA approves Elusys Therapeutics' anthrax treatment to 'protect Americans'

22 March 2016

US biopharmaceutical firm Elusys Therapeutics has received Food and Drug Administration approval for its Anthim (obiltoxaximab) injection for the treatment of inhalational anthrax.

Anthim is indicated for use in combination with appropriate antibacterial drugs by adults and pediatric patients for the treatment of the life-threatening disease, caused by bacillus anthracis.

Cases of inhalational anthrax in humans can occur due to the intentional spread of bacillus anthracis spores as a biowarfare or bioterrorism agent. Bacillus anthracis spores introduced through the lungs lead to inhalational anthrax, which is deadly in humans.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK